TNFerade(TM) Phase III Data Presented at ASCO

...-care (SOC) arm compared to the patients receiving soc alone (Hazard Ratio = 0.75; 95% Confidence Interva...velopment commented on the poster, noting, "In the soc patients, 75% of the patients died within approximately 11.8 months. However, in the TNFerade plus soc group, 75% of the patients did not die until appro...

Clinical Update - Debio 025 in Hepatitis C

...io 025. Three different triple combination regimens will be compared to the soc treatment. The Company aims to evaluate whether there is an increase in the... < 10 U/mL 24 weeks after treatment end) with Debio 025, compared to the soc treatment. The trial will include 272 treatment-naive chronic HCV genotype ...

Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C

...22 of 25) patients receiving R7128 1000mg BID with soc for 4 weeks achieved undetectable HCV RNA levels (...1000mg BID with SOC was comparable to placebo with soc in Cohort 3. One patient was discontinued from the...en at the dose of 500mg, R7128 in combination with soc has demonstrated a greater percentage of RVR compa...

New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering

...gh blockade of angiotensin II receptors. J Am soc Hypertension 2008;2(3);165-172 2. Smith, Ronalde...gh blockade of angiotensin II receptors. J Am soc Hypertension 2008;2(3);165-172 3. Intengan, HD e...gh blockade of angiotensin II receptors. J Am soc Hypertension 2008;2(3);165-172 20. Smith, Ronalde...

Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008

...nide followed by 36 weeks of nitazoxanide plus soc with peginterferon plus ribavirin (a triple regime...ts, combination therapy with nitazoxanide plus soc resulted in a SVR24 rate of 79%, compared with 50% for those treated with soc without nitazoxanide (P=0.023). When nitazoxanide ...

New Pfizer Oncology Data Across Numerous Cancer Types to be Presented at ASCO

...rst, second and later lines, as both a single agent and in various combinations, including: combined with standard of care (SOC) chemotherapies versus soc chemotherapies alone and combined with SOC chemotherapies versus other targeted therapies. The studies will evaluate sunitinib malate in patients with...

GenVec Announces Update of Safety and Efficacy Data from Pivotal Phase II/III PACT Study of TNFerade at ASCO

...val was 19.3 months for patients in the TNFerade + soc arm versus 11.1 months for patients receiving stan...atients in the TNFerade + SOC group and 11% in the soc group. The safety analysis indicated that there .... Seventy percent of patients receiving TNFerade + soc and 78% of those receiving...

New Study Shows That telmisartan has Greater Renoprotective Potential Thanlosartan in Hypertensive Patients With Type 2 Diabetes

...ed 06-2007. (5) Yue JL et al. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am soc Nephrol. 2001; 12:2735-8. (6) Bakris G et al. Comparative long term effects of two AT1 receptor blockers on proteinuria in p...